A novel monoclonal immunoglobulin, Pritoxaximab – formerly known as DXX00601 – presents significant promise within the management of severe immune reaction (TRALI). Created by Bio-X, Pritoxaximab works by https://www.targetmol.com/compound/pritoxaximab